ARVINAS, INC.(ARVN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,765 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ARVN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ARVINAS, INC. (ARVN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARVN at 13.9/100 on a 32-signal composite quality model, placing it at rank #2,765 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.1) and free cash flow (6.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ARVINAS, INC. reports quarterly revenue of $15.6M, net income of $-57.6M, free cash flow of $-70.5M. Top institutional holders of ARVN by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, D. E. Shaw & Co.,, based on the most recent SEC filings. ARVN trades on the Nasdaq exchange and files with the SEC under CIK 1655759. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARVN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ARVINAS, INC. directly from SEC EDGAR. ARVINAS, INC.'s 13F Pro composite quality score has ranged between 8 and 74 since 2021, currently 13.9 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q1 2026
$15.6M
Net Income
Q1 2026
$-57.6M
Free Cash Flow
Q1 2026
$-70.5M
D/E Ratio
Q1 2026
0.00
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-0.3% YoYNet Income
+59.3% YoYOperating Income
+52.6% YoYEPS (Diluted)
+58.8% YoYTotal Assets
-34.2% YoYTotal Debt
-20.0% YoYOp. Cash Flow
-5.6% YoY| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $262.6M -0.3% | $263.4M +100.5% | $131.4M +145.1% | $53.6M +106.9% | $25.9M +241.7% | $7.6M |
| Net Income | $-81.0M +59.3% | $-199.0M +29.6% | $-282.5M -47.9% | $-191.0M -60.1% | $-119.3M -396.1% | $-24.0M |
| Operating Income | $-118.5M +52.6% | $-250.2M +4.9% | $-263.2M -39.7% | $-188.4M -56.0% | $-120.8M -387.9% | $-24.8M |
| EPS (Diluted) | $-1.14 +58.8% | $-2.77 +47.8% | $-5.31 -39.0% | $-3.82 -26.5% | $-3.02 | — |
| Total Assets | $717.9M -34.2% | $1.09B -14.0% | $1.27B -19.8% | $1.58B +120.5% | $717.4M +973.1% | $66.8M |
| Total Debt | $800.0K -20.0% | $1.0M +0.0% | $1.0M +0.0% | $1.0M -50.0% | $2.0M +544.4% | $310.4K |
| Operating Cash Flow | $-273.8M -5.6% | $-259.3M +5.2% | $-273.5M -148.9% | $559.4M +723.6% | $-89.7M -1854.3% | $5.1M |
AI Insight: ARVN Financial Trends
ARVN collapsed from $189M revenue and $83M net income in Q1 2025 to $16M revenue and $58M loss in Q1 2026, signaling severe commercial or pipeline setback.
• Revenue plummeted 91% from Q1 2025 ($189M) to Q1 2026 ($16M); net income swung from +$83M profit to −$58M loss.
• Operating cash flow deteriorated across four consecutive quarters (Q4 2025 through Q1 2026), ranging from −$30M to −$95M.
• Equity eroded 35% from $660M (Q1 2025 peak) to $387M (Q1 2026), while debt remained flat at $1M.
⚠ Q1 2025 spike ($189M revenue, $83M net income) appears anomalous—likely one-time event or contract. Subsequent quarters show persistent operating losses.
⚠ Negative operating cash flow for four straight quarters indicates cash burn despite minimal debt; runway sustainability unclear.
AI Insight: ARVN Ratio Trends
ARVN swung from a brief profitability spike in Q1 2025 back to sustained losses, with ROIC collapsing to -65.9% by Q1 2026.
• Q1 2025 showed OpMargin of 37.8% and NPM of 43.9%, but profitability reversed sharply—Q3 2025 OpMargin fell to -104.5%.
• ROIC deteriorated from 43.2% (Q1 2025) to -65.9% (Q1 2026), signaling severe capital destruction.
• ROE and ROA remain deeply negative across the latest four quarters, averaging -61.5% and -36.2% respectively.
⚠ Q1 2025 profitability appears an anomaly; Q2–Q4 2025 and Q1 2026 all show double-digit negative margins, suggesting underlying operational stress.
⚠ Zero leverage (D/E = 0.00) provides no downside cushion if losses persist or cash runway shortens.
Get alerted when ARVN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ARVINAS, INC. including:
Top Institutional Holders of ARVN
BlackRock, Inc.
$72.1M6,797,584 shVANGUARD PORTFOLIO MANAGEMENT LLC
$41.2M3,889,628 shD. E. Shaw & Co., Inc.
$38.6M3,638,567 shPFIZER INC
$34.9M3,457,815 shVANGUARD CAPITAL MANAGEMENT LLC
$28.5M2,689,362 shTCG Crossover Management, LLC
$25.3M2,387,461 shARMISTICE CAPITAL, LLC
$21.0M1,978,000 shTWO SIGMA INVESTMENTS, LP
$19.4M1,832,114 shSTATE STREET CORP
$19.4M1,828,472 shGEODE CAPITAL MANAGEMENT, LLC
$16.5M1,557,107 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $72.1M | 6,797,584 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $41.2M | 3,889,628 |
| D. E. Shaw & Co., Inc. | $38.6M | 3,638,567 |
| PFIZER INC | $34.9M | 3,457,815 |
| VANGUARD CAPITAL MANAGEMENT LLC | $28.5M | 2,689,362 |
| TCG Crossover Management, LLC | $25.3M | 2,387,461 |
| ARMISTICE CAPITAL, LLC | $21.0M | 1,978,000 |
| TWO SIGMA INVESTMENTS, LP | $19.4M | 1,832,114 |
| STATE STREET CORP | $19.4M | 1,828,472 |
| GEODE CAPITAL MANAGEMENT, LLC | $16.5M | 1,557,107 |
More Healthcare Companies
View all Healthcare →Put ARVN on your watchlist
Track score changes the day ARVINAS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ARVN a good stock to buy?
13F Pro's AI-powered analysis of ARVINAS, INC. (ARVN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARVN are available on the ARVN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ARVN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARVN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ARVINAS, INC.'s investment landscape.